| abstract |
sglt2 inhibitors of c-aryl glycoside i are provided sglt2 inhibitor compounds having the formula (i) where r1, r2 and r2a are independently hydrogen, oh, or5 , lower alkyl, cf3, ochf2, ocf3, sr5i or halogen, or two of r1 , r2 and r2a together with the carbons to which they are attached, can form a five-, six- or seven-membered ringed carbocycle or heterocycle; r3 and r4 are independently hydrogen, oh, or5a, oaryl, och2aryl, lower alkyl, cycloalkyl, cf3, -ochf2, -ocf3, halogen, -cn, -co2r5b, -co2h, -cor6b, -ch(oh) r6c, - ch (or5h) r6d, -conr6r6a, -nhcor5c, -nhso2r5d, -nhso2aryl, aryl, -sr5e -sor5f, -so2r5g, -so2aryl, or a heterocycle with five, six, or seven members, or r3 and r4 together with the carbons to which they are attached form a five-, six- or seven-membered ringed heterocycle or carbocycle; r5, r5a, r5b, r5c, r5d, r5e, r5f, r5g, r5h and r5i are independently lower alkyl; r6, r6a, r6b, r6c and r6d are independently hydrogen, alkyl, aryl, alkylaryl or cycloalkyl, or r6 and r6a together with the nitrogen to which they are attached form a five-, six- or seven-membered ring heterocycle; a is o, s, nh or (ch2)n where n is 0 - 3. A method of treating diabetes and related diseases is also provided employing a sglt2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent. |